blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2508535

EP2508535 - Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  06.09.2013
Database last updated on 03.09.2024
Most recent event   Tooltip06.09.2013Application deemed to be withdrawnpublished on 09.10.2013  [2013/41]
Applicant(s)For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101, rue de Tolbiac
75013 Paris / FR
[2012/41]
Inventor(s)01 / Faivre, Jamila
5 rue du Général Delestraint
75016 Paris / FR
02 / Herve, Julie
8 Résidence Delattre De Tassigny
Route des Ponts de Cé
49000 Angers / FR
03 / Clerc, Jérôme
6 rue Toullier
75005 Paris / FR
04 / Brechot, Christian
35 Boulevard Pasteur
75015 Paris / FR
 [2012/41]
Representative(s)Jacobacci Coralis Harle
32, rue de l'Arcade
75008 Paris / FR
[N/P]
Former [2012/41]Coralis Harle
14-16 Rue Ballu
75009 Paris / FR
Application number, filing date12174478.312.09.2007
[2012/41]
Priority number, dateEP2006030094212.09.2006         Original published format: EP 06300942
[2012/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2508535
Date:10.10.2012
Language:EN
[2012/41]
Search report(s)(Supplementary) European search report - dispatched on:EP12.09.2012
ClassificationIPC:C07K14/47, C12N15/79, C12N15/63, C12N15/861, A61K48/00, C12Q1/68
[2012/41]
CPC:
C12N15/85 (EP,US); A61P35/00 (EP); A61P35/02 (EP);
C12N15/113 (EP,US); A61K48/00 (EP,US); C12N2310/111 (EP,US);
C12N2800/107 (EP,US); C12N2800/108 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2012/41]
TitleGerman:Nucleinsäure zur Expression eines relevanten Polynucleotids in Säugetierkrebszellen[2012/41]
English:Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells[2012/41]
French:Acides nucléiques pour l'expression d'un polynucléotide d'intérêt dans des cellules cancéreuses de mammifères[2012/41]
Examination procedure11.04.2013Application deemed to be withdrawn, date of legal effect  [2013/41]
21.05.2013Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2013/41]
Parent application(s)   TooltipEP07803443.6  / EP2069398
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20070803443) is  22.06.2010
Fees paidRenewal fee
29.06.2012Renewal fee patent year 03
29.06.2012Renewal fee patent year 04
29.06.2012Renewal fee patent year 05
02.08.2012Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO2005007832  (CELL GENESYS INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular p.23, l.4 to p.24, l.6; p.32, l.21 to p.34, l.17 and SEQ ID NO: 5 * [Y] 6;
 [XY]US2003152553  (LITTLE ANDREW S [US], et al) [X] 1-3,5,7-15 * the whole document, in particular [0061], [0122-0125], Example 3 and SEQ ID NO: 5 * [Y] 6;
 [XY]WO0173093  (CALYDON INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular Figure 5; p.37, l.14 to p.39, l.2; Examples 1,5,9, SEQ ID NO: 16, claims 24, 58 * [Y] 6;
 [XY]WO0172341  (CALYDON INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular p.25,l.3-9; p.38,l.19 to p.39, l.12; p.69,l.1 to p.70,l.23; Examples 3,5,7,10,14, p.194-197; claims 12,13,31,32,42 * [Y] 6;
 [XY]WO0039319  (CALYDON INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular p.38,l.13 to p.39,l.24; Examples 1,3, claims 13,45,46; Figure 28 * [Y] 6;
 [XY]WO2005112541  (PROYECTO BIOMEDICINA CIMA SL [ES], et al) [X] 1-5,7-15 * the whole document, in particular p.10,l.25 to p.11,l.4; p.18,l.14 to p.19,l.2; p.26,l.13 to p.27,l.29; Figures 2,7; SEQ ID NOs: 7,9,11, claims 8,24,25 * [Y] 6;
 [XY]WO9839465  (CALYDON INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular p.21,l.17-32; SEQ ID NO: 2 * [Y] 6;
 [A]US2006068370  (WANG MEI-CHIH [TW], et al) [A] 1-15;
 [X]  - "Homo sapiens BAC clone RP11-580P21 from 4, complete sequence.", EMBL, (20020129), Database accession no. AC108157, URL: EBI, XP002421520 [X] 4 * see sequence, in particular 97911-102095 *
 [Y]  - MANDELL ROBERT B ET AL, "Radioisotope concentrator gene therapy using the sodium/iodide symporter gene", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (19990201), vol. 59, no. 3, ISSN 0008-5472, pages 661 - 668, XP002134372 [Y] 6 * the whole document *
 [Y]  - FILETTI S ET AL, "Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism", EUROPEAN JOURNAL OF ENDOCRINOLOGY, SCANDINAVIAN UNIVERSITY PRESS, NO, (199911), vol. 141, no. 5, ISSN 0804-4643, pages 443 - 457, XP002258682 [Y] 6 * the whole document *

DOI:   http://dx.doi.org/10.1530/eje.0.1410443
 [Y]  - SPITZWEG C ET AL, "Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (20001115), vol. 60, no. 22, ISSN 0008-5472, pages 6526 - 6530, XP002258676 [Y] 6 * the whole document *
 [A]  - WATANABE K ET AL, "CELL-SPECIFIC ENHANCER ACTIVITY IN A FAR UPSTREAM REGION OF THE HUMAN ALPHA FETOPROTEIN GENE", JOURNAL OF BIOLOGICAL CHEMISTRY, (1987), vol. 262, no. 10, ISSN 0021-9258, pages 4812 - 4818, XP002067679 [A] 1-15
 [A]  - AKIO IDO ET AL, "GENE THERAPY FOR HEPATOMA CELLS USING A RETROVIRUS VECTOR CARRYING HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE UNDER THE CONTROL OF HUMAN ALPHA-FETOPROTEIN GENE PROMOTER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (19950715), vol. 55, ISSN 0008-5472, pages 3105 - 3109, XP002123061 [A] 1-15
 [A]  - "Homo sapiens AFP gene for alpha-fetoprotein, promoter region.", EMBL, (20010306), Database accession no. AB053572, URL: EBI, XP002421521 [A] 1-15
by applicantWO2004112824
 WO2004011824
 WO9845443
 US2005261232
 US5093246
 US5116742
 US2003105043
 US2003195164
 US2005261249
 US2005113328
 US2005026860
 US2005026857
 US2004043950
 US2004009156
 US2003158130
 US2003036521
 WO9728175
 WO9412650
 WO9412649
 WO9412629
 US5922576
 WO9402595
 WO9323569
 WO9905094
 WO9904819
 WO9610391
 WO9610390
 WO9610392
    - HANAHAN D.; WEINBERG R. A., CELL, (2000), vol. 100, pages 57 - 70
    - SCHALLY; NAGY, EUROP J ENDOCTINOL, (1999), vol. 141, page 1
    - WHITNEY ET AL., CANCER, (1995), vol. 76, page 20
    - LASKE ET AL., NEUROSURG, (1997), vol. 41, page 1039
    - VOSE ET AL., LEUKEMIA & LYMPHOMA, (2000), vol. 38, page 91
    - MURASZKO ET AL., CANCER RES, (1983), vol. 53, page 3752
    - FAULK ET AL., MOL BIOTHERAPY, (1990), vol. 2, page 57
    - BERCZI ET AL., ARCH BIOCHEM BIOPHY, (1993), vol. 300, page 356
    - BEYER ET AL., J MED CHEM, (1998), vol. 41, page 2701
    - KRATZ ET AL., J PHARM SCI, (1998), vol. 87, page 338
    - BINLEY K. ET AL., GENE THERAPY, (1999), vol. 6, pages 1721 - 1727
    - HEISE C. ET AL., NATURE MEDICINE, (1997), vol. 3, pages 639 - 645
    - PARR M. J. ET AL., NATURE MEDICINE, (1997), vol. 3, pages 1145 - 1149
    - BENIHOUD K. ET AL., CURR. OPIN. BIOTECHNOL., (1999), vol. 10, pages 440 - 447
    - SMITH; WATERMAN, ADD. APL. MATH., (1981), vol. 2, page 482
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443
    - PEARSON; LIPMAN, PROC. NATL. ACAD. SCI., (1988), vol. 85, page 2444
    - WATANABE ET AL., J. BIOL., CHEM., (1987), vol. 282, no. 10, pages 4812 - 4818
    - LOVANNA ET AL., J BIOL CHEM, (1991), vol. 266, pages 24664 - 24669
    - DUSETTI ET AL., J BIOL CHEM, (1995), vol. 270, no. 38, pages 22417 - 22421
    - SARKAR ET AL., BIOTECHNIQUES SUPPL, (2002), pages 30 - 39
    - FISHER ET AL., CANCER BIOL THER, (2003), vol. 2, pages 23 - 37
    - ANDERSON ET AL., CURR OPIN PHARMACOL, (2004), vol. 4, no. 4, pages 314 - 320
    - YOSHIDA ET AL., CANCER SCI, (2004), vol. 95, no. 11, pages 858 - 865
    - HAUPT ET AL., CELL CYCLE, (2004), vol. 3, no. 7, pages 912 - 916
    - CHAN ET AL., CLIN EXP PHARMACOL PHYSIOL, (2004), vol. 31, no. 3, pages 119 - 128
    - SANSAL ET AL., J CLIN ONCOL, (2004), vol. 22, no. 14, pages 2954 - 63
    - GOWARDHAN ET AL., PROSTATE, (2004), vol. 61, no. 1, pages 50 - 59
    - LIU ET AL., CANCER GENE THER, (2004), vol. 11, no. 11, pages 748 - 756
    - QUI ET AL., HEPATOBILIARY PANCREAT DIS INT, (2004), vol. 3, no. 4, pages 552 - 557
    - SARKAR ET AL., PHARMACOL THER, (2004), vol. 104, no. 2, pages 101 - 115
    - LEIBERMANN ET AL., LEUKEMIA, (2002), vol. 16, no. 4, pages 527 - 41
    - MITROFANOVA ET AL., CLIN CANCER RES, (2004), vol. 10, no. 20, pages 6969 - 6976
    - J. GOMEZ-NAVARRO ET AL., "Gene therapy for cancer", EUROPEAN JOURNAL OF CANCER, (1999), vol. 35, doi:doi:10.1016/S0959-8049(99)00061-1, pages 867 - 885, XP002959624

DOI:   http://dx.doi.org/10.1016/S0959-8049(99)00061-1
    - J. A. ROTH ET AL., "Gene therapy for cancer: what have we done and where are we going?", JOURNAL OF THE NATIONAL CANCER INSTITUTE, (1997), vol. 89, no. 1, pages 21 - 39
    - D. KLATZMANN ET AL., "A Phase 1/11 dose-escalation study of herpes simplex virus type 1 thymidine kinase ''suicide'' gene therapy for recurrent metastatic melanoma", HUMAN GENE THERAPY, (1998), vol. 9, pages 2585 - 2894
    - J. R. HERMAN ET AL., "In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial", HUMAN GENE THERAPY, (1999), vol. 10, doi:doi:10.1089/10430349950018229, pages 1239 - 1249, XP000983940

DOI:   http://dx.doi.org/10.1089/10430349950018229
    - BORKHARDT, A., "Blocking oncogenes in malignant cells by RNA interference : New hope for a highly specific cancer treatment?", CANCER CELL, (2002), vol. 2, no. 3, doi:doi:10.1016/S1535-6108(02)00129-0, pages 167 - 8, XP009006463

DOI:   http://dx.doi.org/10.1016/S1535-6108(02)00129-0
    - WILDA, M. ET AL., "Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi", ONCOGENE, (2002), vol. 21, no. 37, doi:doi:10.1038/sj.onc.1205653, pages 5716 - 24, XP009009806

DOI:   http://dx.doi.org/10.1038/sj.onc.1205653
    - BRUMMELKAMP, T. R.; R. BERNARDS; R. AGAMI, "Stable suppression of tumourigenicity by virus-mediated RNA interference", CANCER CELL, (2002), vol. 2, no. 3, doi:doi:10.1016/S1535-6108(02)00122-8, pages 243 - 7, XP009006464

DOI:   http://dx.doi.org/10.1016/S1535-6108(02)00122-8
    - P. D. ZAMORE, SCIENCE, (2002), vol. 296, page 1265
    - HAMMOND ET AL., NAT. REV. GENET, (2001), vol. 2, pages 110 - 119
    - NORRIS ET AL., "Design and testing of ribozymes for cancer gene therapy", ADV. EXP MED. BIOL., (2000), vol. 465, pages 293 - 301
    - HASELHOFF ET AL., NATURE, (1988), vol. 334, pages 585 - 591
    - FAIVRE ET AL., CANCER RESEARCH, (2004), vol. 64, pages 8045 - 8051
    - HARRINGTON ET AL., NAT GENET, (1997), vol. 15, page 345
    - SMITH, ANNU. REV. MICROBIOL., (1995), vol. 49, page 807
    - ROSENFELD ET AL., CELL, (1992), vol. 68, page 143
    - LOGAN; SHENK, PROC. NATL. ACAD. SCI., (1984), vol. 81, page 3655
    - MILLER ET AL., MOL. CELL. BIOL., (1990), vol. 10, page 4239
    - KOLBERG, J. NIH RES., (1992), vol. 4, page 43
    - CORNETTA ET AL., HUM. GENE THER., (1991), vol. 2, page 215
    - TONG-CHUAN ET AL., PROC. NATL. ACAD. SCI. USA, (1998), vol. 95, pages 2590 - 2514
    - AKHTAR ET AL., TRENDS CELL BIO., (1992), vol. 2, page 139
    - GOLD, NEUROSCIENCE, (1997), vol. 76, pages 1153 - 1158
    - HO ET AL., CURR. OPIN. MOL. THER., (1999), vol. 1, pages 336 - 343
    - GROOTHUIS ET AL., J NEUROVIROL., (1997), vol. 3, pages 387 - 400
    - JOLLIET-RIANT; TILLEMENT, FUNDAM. CLIN. PHARMACOL., (1999), vol. 13, pages 16 - 26
    - EMERICH, DF ET AL., CELL TRANSPLANT, (1999), vol. 8, pages 47 - 58
    - PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, (1999), vol. 23, pages 941 - 949
    - BOADO ET AL., J. PHARM. SCI., (1998), vol. 87, pages 1308 - 1315
    - TYLER ET AL., FEBS LETT., (1999), vol. 421, pages 280 - 284
    - PARDRIDGE ET AL., PNAS USA, (1995), vol. 92, pages 5592 - 5596
    - BOADO, ADV. DRUG DELIVERY REV., (1995), vol. 15, pages 73 - 107
    - ALDRIAN-HERRADA ET AL., NUCLEIC ACIDS RES., (1998), vol. 26, pages 4910 - 4916
    - TYLER ET AL., PNAS USA, (1999), vol. 96, pages 7053 - 7058
    - LASIC ET AL., CHEM. REV., (1995), vol. 95, pages 2601 - 2627
    - ISHIWATA ET AL., CHEM. PHARM. BULL., (1995), vol. 43, pages 1005 - 1011
    - LASIC ET AL., SCIENCE, (1995), vol. 267, pages 1275 - 1276
    - OKU ET AL., BIOCHIM. BIOPHYS. ACTA, (1995), vol. 1238, pages 86 - 90
    - LIU ET AL., J. BIOL. CHEM., (1995), vol. 42, pages 24864 - 24870
    - HE ET AL., P.N.A.S, (1998), vol. 95, pages 2509 - 14
 WO2001US13000
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.